Asset profile
JTT-861
Small molecule
Evidence outlook · lead readout
NCT06017609 · Chronic Heart Failure
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06017609: The study randomized 314 participants to two JTT-861 dose groups or placebo and used quadruple blinding. Its primary outcomes were mainly changes in echocardiographic measurements and NT-proBNP, which are surrogate measures, and no results are posted to show whether the planned comparisons were met.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.